Immix Biopharma, Inc.
No enriched coverage for $IMMX in the last 7 days.
No SEC Form 4 filings for $IMMX in the last 30 days.
A financial analyst has increased the price target for Immix Biopharma (IMMX) by 25.64%. The new target is set at $16.66. This adjustment indicates a more optimistic outlook on the company's stock valuation from the analyst.
Immix Biopharma (NASDAQ: IMMX) reported quarterly earnings per share (EPS) of ($0.28), missing the consensus estimate of ($0.16) by ($0.12). Shares experienced a 6.5% decline to $8.15 following the announcement. Despite the earnings miss, analysts maintain a "Moderate Buy" consensus rating with an average target price of $18.00, and institutional investors have recently increased their holdings in the company.
Immix Biopharma's lead CAR-T candidate, NXC-201, shows promise in treating relapsed/refractory amyloid light chain amyloidosis (r/r ALA) based on positive clinical updates from the NEXICART-2 trial. The company anticipates a final readout in mid-2026 and plans to submit a biologics license application (BLA) to the FDA by the end of 2026, provided results remain supportive. Alongside these developments, a $100 million fund-raise is expected to finance operations until mid-2027, leading Edison Investment Research to increase Immix's valuation to $373.2 million, or $7.2 per share.
